AbbVie - Phase 2 Study of Upadacitinib Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

NORTH CHICAGO - AbbVie today announced the results of the Phase 2 SLEek study evaluating upadacitinib alone and in combination [ABBV-599 high dose ] in adults with moderately to severely active... | June 1, 2023

Related Keywords

Oklahoma ,United States ,Roopal Thakkar ,Kristin Pawliw ,Joan Merrill ,Exchange Commission ,Lupus Erythematosus National Assessment ,Arthritis Clinical Immunology Research Program ,European Congress ,Oklahoma Medical Research Foundation ,Flare Index ,Lupus Low Disease Activity State ,Medical Research Foundation ,Clinical Immunology Research ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Risk Factors ,Quarterly Reports ,News Publishing ,Abbvie Inc Stock Exchange ,News ,Information ,Press Release ,North ,Chicago ,Abbvie ,Oday ,Nnounced ,The ,Results ,F ,Hase , ,Leek ,Study ,Valuating ,Upadacitinib ,Alone ,End ,N ,Combination ,Thigh ,Nose ,Adults ,Ith ,Moderately ,O ,Everely Abbv Us00287y1091 ,